Analyst consensus rating
CG Oncology Analyst Rating: Strong Buy
CGON is rated Strong Buy by 13 analysts with a $91.08 target. As of 2026-08-23.
Direct answer
CG Oncology's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $91.08.
Forecast evidence checked August 23, 2026.
Get free CG Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $79.81
- Average price target
- $91.08
- High price target
- $108.00
- Low price target
- $79.00
- Low target gap
- -1%
- Target upside
- +14.1%
- High target gap
- +35.3%
- Target range width
- 36.3%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for CG Oncology?
CG Oncology has a verified Strong Buy consensus. The same dataset has an average price target of $91.08.
How far are CG Oncology's low and high targets from the recorded price?
The low target implies -1%, while the high target implies +35.3%.
How many analysts are included in CG Oncology's consensus?
The verified consensus includes 13 analysts.
How is CG Oncology's target upside or downside calculated?
The average target of $91.08 is divided by the recorded price of $79.81, then one is subtracted to produce +14.1%. This does not guarantee a future return.
When was CG Oncology's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.